REDAVIA
18.6.2020 10:02:13 CEST | Business Wire | Press release
REDAVIA , a global market leader of cost-effective, reliable, and clean solar power for businesses, has signed four new COVID-19 Resilience Leases in Ghana and Kenya, offering these businesses six months of free solar to withstand the COVID crisis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200618005033/en/
Siginon Aviation is a ground handling company based at Jomo Kenyatta International Airport (JKIA) in Nairobi, Kenya. Its Corporate Social Responsibility (CSR) policy embraces environmental conservation for its communities’ current and future generations, and REDAVIA’s free solar power solution supports this CSR endeavor well.
“The partnership with REDAVIA comes at a time when the green agenda is a key business objective. This solar power solution gives Siginon Aviation the opportunity to reaffirm its commitment as a responsible corporate citizen,” said Edwin Ronoh, Siginon Group Finance Leader.
Wonder Feeds Ltd recently upgraded its factory to accommodate its growing animal feed products business. When the COVID crisis hit the economy, management maintained product prices for customers despite the increase of raw material costs, leaving the company with higher operating expenses. Faced with these economics, Managing Director Abdul Parkar was thrilled when REDAVIA extended the same helping hand to him that he extended to his customers.
Methodist University College Ghana President Akwasi Asabere-Ameyaw had been searching for an alternative energy solution for some time now, but no solution fit until REDAVIA offered his institution the opportunity to reduce carbon emissions while also making savings that can be reinvested into the university.
Emigoh Ghana Ltd states that its philosophy and fundamental purpose is to make the future better and worth living by building a first-class organization that caters to Ghanaian people through quality health and nutrition.
Stephen Eku, CEO of Emigoh, said, “After working for years to create a premium, sustainable food supply chain, I am delighted to partner with a company like REDAVIA that will allow us to also reduce our carbon footprint in a cost-efficient way.”
COVID-19 has disrupted African businesses significantly. In this challenging time, REDAVIA enables sound businesses to reduce their operating costs with a free solar plant leasing service. REDAVIA has introduced the COVID-19 Resilience Lease, which provides solar power plants to business customers for six months, completely for free.
Erwin Spolders, CEO & founder of REDAVIA, said, “We are glad to be able to make a difference for our business partners in this time of need and start win-win relationships that will last for decades. The COVID Resilience Lease Program is already a huge success, and we are keen to scale up the program further. We invite more companies to apply.”
About REDAVIA
REDAVIA offers solar power for businesses in sub-Saharan Africa. The REDAVIA system is based on a pre-configured model, including high-performance solar modules and electrical components. It is easy to ship, set up, scale, and redeploy. Businesses benefit from a cost-effective, reliable, clean energy solution with minimal upfront investment. www.redaviasolar.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200618005033/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom